EBS | tickerfilter.com

Fundamental analysis

16%

Profitability 2%

Dept financing 18%

Liquidity 17%

Performance 29%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

2.47%

1 Month

-15.74%

3 Months

39.73%

6 Months

20.46%

1 Year

234.68%

2 Year

-24.55%

Key data

Stock price

$8.30

P/E Ratio

-0.74

DAY RANGE

$6.90 - $8.23

EPS

-$11.31

52 WEEK RANGE

$1.58 - $15.10

52 WEEK CHANGE

$245.83

MARKET CAP

439.654 M

YIELD

N/A

SHARES OUTSTANDING

52.907 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/07/2024

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,199,392

AVERAGE 30 VOLUME

$981,520

Company detail

CEO: Robert G. Kramer
Region: US
Website: emergentbiosolutions.com
Employees: 2,420
IPO year: -

Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Emergent BioSolutions focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose.

EBS - Emergent BioSolutions Inc.